January 9th - 10th, Synaps held its latest consortium meeting in the University of Lille (France). This meeting was scheduled to update all partners about SYNAPS progress and mostly to prepare the upcoming final project proposal for the H2020 call on New therapies for rare diseases (SC1-PM-08-2017).
After the previous consortium held the September 5th and 6th 2016, several milestones have been validated in order to lead to a successful H2020 application and to reinforce future collaborations. This consortium meeting was scheduled to update all partners about SYNAPS progress and mostly to prepare the upcoming final project proposal. All the partners were represented :
Inserm U1189 - S. Mordon / M. Vermandel / C. Dupont / F. Lecomte / A.S. Vignion-Dewalle
Lille University - M. Gompel
University Hospital of Lille – Neurosurgery Dept – N. Reyns / F. Nosal
LEITAT Technological Center – G. Quintas
University of Brussels- Neurosurgery Dept - ERASME – F. Lefranc
Intermedic – X. Arcusa / R. Serra
IDDI – E. Saad
Medizinische Universität Graz – Neurosurgery Dept - G. Von Campe
ECRIN – A. Strader
ONCORADIOMICS – S. Walsh
OP2 Drug – F. Marin
SATT NORD - M. Fisichella
Inserm U1189 - S. Mordon / M. Vermandel / C. Dupont / F. Lecomte / A.S. Vignion-Dewalle
Lille University - M. Gompel
University Hospital of Lille – Neurosurgery Dept – N. Reyns / F. Nosal
LEITAT Technological Center – G. Quintas
University of Brussels- Neurosurgery Dept - ERASME – F. Lefranc
Intermedic – X. Arcusa / R. Serra
IDDI – E. Saad
Medizinische Universität Graz – Neurosurgery Dept - G. Von Campe
ECRIN – A. Strader
ONCORADIOMICS – S. Walsh
OP2 Drug – F. Marin
SATT NORD - M. Fisichella
